fbpx
Canadian Ophthalmological Society

Vision Health Month: Canada’s Aging Population Need to Prioritize Eye Health and Vision Loss Prevention

May is Vision Health Month, and the Canadian Ophthalmological Society (COS) wants to stress the importance of vision health care, especially when assessing the overall needs of Canadian seniors. According to a 2022 survey by the COS, 4 in 10 Canadians (41%) have experienced or been diagnosed with at least one change to their eye health over the past two years – with this number increasing to 56% among respondents aged 65 and over.

More than 1.2 million Canadians live with vision loss today, and over 8 million Canadians live with one of the four major eye diseases. Blinding diseases affect older adults (55+) at much higher rates, and as Canada’s population ages, the number of individuals affected by vision impairment will rise.

In an effort to address this, the COS is taking part in the National Seniors Council’s Aging at Home consultations – an initiative that aims to engage various stakeholders, including healthcare experts, to identify gaps and further support required for Canadians who wish to age within the comfort of their own homes.

“Vision loss can have a significant impact on the physical, cognitive, and emotional well-being of seniors, and their ability to live independently,” says Dr. Phil Hooper, President of the Canadian Ophthalmological Society. “Health care needs increase with age and many seniors require coordinated care that involves both surgical and medical interventions to address their vision loss, so developing solutions for this concern now will further support the Aging at Home initiative which, in turn, will allow seniors to live at home safely.”

Education and awareness of eye health and eye diseases are crucial to help reduce the risk of vision loss amongst seniors. While most Canadians are familiar (62%) with cataracts, only one-quarter (27%) of Canadians know that cataracts are the leading cause of blindness in the country. Less than half (47%) are familiar with glaucoma and only 39% are familiar with age-related macular degeneration (AMD) which is the second leading cause of blindness. Fewer are aware of diabetic retinopathy (22%) and contact lens-associated dry eye disease (26%).

Seniors with vision loss are more likely to enter residential care, and they may also be more likely to access residential care earlier because of vision loss. To minimize the risk of vision loss among seniors, the COS recommends:

  • Focus on screening and collaboration among the eye care team: Frequent and regular eye exams will allow for earlier detection of blinding eye diseases, which will ensure earlier treatment to help delay the onset of vision loss.
  • Increasing residency positions: One of the main concerns about the current surgical backlog is that over time it will worsen due to the growing need and there won’t be enough trained ophthalmologists. There is a need to increase the number of residency positions in ophthalmology across Canada and develop new models to allow the entry of internationally trained physicians.
  • Creating a National Vision Health Desk: This will provide the pan-Canadian view necessary to help integrate care and increase access to vision health across Canada. A national-level view will help understand issues and address the lack of coordination at the government and patient levels.

Click HERE for the full press release.

Featured Posts

Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read more
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read more
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read more
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read more
Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read More
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read More
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read More
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read More
Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read more
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read more
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read more
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read more
Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read more
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read more
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read more
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read more